Home › Companies › MPLT

MapLight Therapeutics

Market cap $365M 55.6M shares (vendor count, Nov 18, 2026) × $6.57 close Nov 17, 2026 · share count from the market-data vendor, not the SEC cover page

Most recent annual filing: 2026-03-26

Catalyst timeline

5 trackedQuarter catalyst calendar →
  1. ML-055 next-gen M1 corporate update2026ML-055 next-gen M1 corporate update, 2026, routine
  2. ML-009 PAM corporate update2027ML-009 PAM corporate update, 2027, routine
  3. ML-021 M4 antagonist corporate update2027ML-021 M4 antagonist corporate update, 2027, routine
  4. ML-007C-MA VISTA Ph2 topline2H 2027ML-007C-MA VISTA Ph2 topline, 2H 2027, thesis-defining
  5. ZEPHYR-2 Study 311 topline2028ZEPHYR-2 Study 311 topline, 2028, material

Bar width shows how precise the guidance is — a pin is a stated date, a wide band a six-month window. Deeper blue means more of the thesis rides on the event; it is not a view on the stock.

Pipeline (3 active programs)

Technology platforms

MapLight Discovery Platform

Circuit-based CNS drug discovery platform combining optogenetics, single-cell transcriptomics, and STARmap spatial transcriptomics to identify neural circuits causally linked to CNS disease symptoms and discover druggable targets within those circuits for therapeutic modulation.

Discontinued (3)

Capital (as filed)

Cash
$55.6M cash and cash equivalents · Sep 30, 2026 (10-Q)
Short-term investments
$229M Sep 30, 2026
Long-term investments
$179M Sep 30, 2026
Operating cash flow
−$35.7M quarter Jun 30, 2026 → Sep 30, 2026, year-to-date difference (10-Q)
As stated in coverage
$463M cash, runway 2028 per the update of Nov 16, 2026 — the company's own words as read there, not the filed figure

Offering documents (1)

Cash, investments and operating cash flow are the company's own XBRL facts as filed with the SEC, each shown with its period end and tag. As-stated figures come from the company's own words as read in Biotech Distilled coverage, dated, and routinely count securities and planned financing that a balance sheet does not. Offering rows are the SEC cover pages as filed. Not investment advice. Figures as of Nov 18, 2026.

Biotech Distilled coverage (6)

Articles open on Substack. Some are subscriber-only; those marked ★ Distilled Pro are for Distilled Pro members.

Verdict history (6 calls)

Every verdict Biotech Distilled has published on MapLight Therapeutics, oldest first — the full history, never a selection. How calls are scored: the track record.

  1. Watch MapLight Therapeutics (MPLT) — Scientific Deep Dive for ML-007C-MA, ML-004, and Pipeline Products ZEPHYR met its primary endpoint but delivered a weak effect size (0.37), the QD arm failed contradicting the company's own PK/PD model, the negative-symptom key secondary went unreported, composition-of-matter patents expire 2031–2032, and the balance sheet cannot fund a confirmatory Phase 3 to readout.
  2. Watch UPDATE: MapLight Therapeutics (MPLT) - Somebody Sold the Bounce Novo Holdings dumped ~1.6M shares into the post-ZEPHYR bounce, thinning the specialist crossover book further; the four unresolved scientific questions are unchanged and the supply overhang now has a named clearing price of $12.00.
  3. Speculative buy speculative UPDATE: MapLight Therapeutics (MPLT) - Now We Know Who Bought It Catalyst4 committed ~$15.3M of working capital at ~$12.65 average to reach 47.9%, providing a named funded buyer against the supply overhang, while roughly half the market cap remains cash and VISTA offers a separate shot on goal in an indication with zero approved therapies.
  4. Hold UPDATE: MapLight Therapeutics (MPLT) - The Missing Endpoint Shows Up The $150M raise at $11.38 clears the financing overhang and extends runway through 2028, but the disclosed PANSS negative Marder factor (ES 0.18, p=0.244) confirms the July silence was a miss, and the raise appears to be a marketed deal without insider participation — close to the reversal condition set on August 4.
  5. Speculative buy speculative UPDATE: MapLight Therapeutics (MPLT) - Catalyst4 Bought the Deal Catalyst4 funded 55.6% of the $150M PIPE at $11.38 and reached 49.9%, meaning the raise was insider-anchored rather than a marketed deal — negating the reversal condition set on August 4 — while cash now runs through 2028 covering both VISTA and ZEPHYR-2.
  6. Hold UPDATE: MapLight Therapeutics (MPLT) - An ATM Below Cash MapLight filed a $100M ATM below cash per share, T. Rowe has sold most of its stake, the EOP2 meeting remains unscheduled, and the Phase 3 now reads out in 2028 — both conditions for reversal are moving the wrong way, though the stock trading at or below cash and Deep Track's entry limit the downside.

Every verdict Biotech Distilled has published on this company, in order, with the post it came from — the full history, never a selection. Position figures are the same ones shown on /track-record, computed by the same method. Editorial opinion, not investment advice.

Timing, in the company's words (3 quotes from 3 filings)

Sentences quoted verbatim from the company's SEC filings, newest filing first. Each sits under the filing it appeared in; the "matched to" tag names the calendar row it was read for.

Timing sentences quoted from the company's own SEC filings, each under the filing it appeared in. The 'matched to' tag is the calendar row the sentence was read for; the filing is the source. Not investment advice.

Filings & releases (29)

SEC filings from EDGAR and press releases captured from the company's investor-relations site, newest first. Releases captured from Jul 27, 2026; filings from March 2026. Summaries come from the BD update that read the document; "BD extracted" counts point at the pipeline table above. All companies →

9 more filings (13G holder notices, S-8, proxy material, SEC correspondence …)